1 / 23

A GLOBAL MEDICAL DEVICE COMPANY AND A LEADER IN THE TREATMENT OF CARDIOVASCULAR DISEASES

3,700 employees in the world Over 5,000 hospitals served around the world One million patients treated with Sorin Group’s devices every year in over 80 countries Listed on the Milan Stock Exchange. A GLOBAL MEDICAL DEVICE COMPANY AND A LEADER IN THE TREATMENT OF CARDIOVASCULAR DISEASES.

damon
Download Presentation

A GLOBAL MEDICAL DEVICE COMPANY AND A LEADER IN THE TREATMENT OF CARDIOVASCULAR DISEASES

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 3,700 employees in the world Over 5,000 hospitals served around the world One million patients treated with Sorin Group’s devices every year in over 80 countries Listed on the Milan Stock Exchange A GLOBAL MEDICAL DEVICE COMPANY AND A LEADER IN THE TREATMENT OF CARDIOVASCULAR DISEASES

  2. A GLOBAL REACH • Focusing on 3 core Business Units • The World Leader in Cardiopulmonary with a 35% market share worldwide • A strong presence in Europe and in Japan in the Cardiac Rhythm Management market • #2 Heart Valve Company in Europe

  3. SORIN GROUP SALESBY THERAPEUTIC AREA - 2010 HEARTVALVES • €120.5 millionTissue and mechanical valves, annuloplasty rings for heart valve replacement and repair 16% CARDIOPULMONARY • € 338 millionHeart-lung machines, oxygenators, autotransfusion systems when extracorporeal circulation is needed during prosthetic replacement, bypass, valve repair 46% € 746 million 38% CARDIAC RHYTHM MANAGEMENT (CRM) • €285 millionImplantable cardiac defibrillator (ICD) and pacemaker systems to restore normal cardiac rhythm, cardiac resynchronization therapy (CRT) systems to treat heart failure and Holter systems

  4. SORIN GROUPFOUNDED IN 1956 AS A JOINT VENTURE RESEARCH PROJECT SORIN MANUFACTURING FACILITIES FIAT Automotive manufacturer (Turin) • In The 60s MONTECATINI • Today Chemical company (Milan)

  5. MAJOR MILESTONES (1) LISTING ON MILAN STOCK EXCHANGE ENTERING SORIN GROUP COMPANIES FOUNDATION 40’s 70’s 80’s ’92 ’99 ’01 ’03 January 2004 Sorin Biomedica Stöckert / Dideco Cobe Cardiovascular ELA Medical Carbomedics

  6. RECENT MILESTONES (2) EXPANDING PRODUCT PORTFOLIO STREAMLINING ORGANIZATION FOCUSING ON CORE ACTIVITIES DISTRIBUTOR ACQUISITIONS 2011 2010 2009 2011 ACQUISITIONS 2008 DIVESTITURES EVH (Endoscopic Vessel Harvesting) Vascular Therapy Austria Renal Care Netherlands Gish (Oxygenators) Angel™ (Whole Blood Separation System) Poland

  7. A PORTFOLIO OF INNOVATIVE PRODUCTS Heart-Lung Machines Oxygenators Autotransfusion Systems CARDIOPULMONARY Heart failure Management Systems Tachyarrhythmia Management Systems Bradyarrhythmia Management Systems CARDIAC RHYTHM MANAGEMENT (CRM) Tissue Valves Mechanical Valves Self-Anchoring, Sutureless Valve HEARTVALVES

  8. A TRADITION OF EXCELLENCE IN INNOVATION • EUR 66.9 million dedicated to R&D i.e. 9% of sales revenues • 14% of employees work in R&D Over 500 people in North America, France, Italy and Germany • Numerous partnerships with cardiology specialists and cardiac surgeons as well as world-renowned universities and research centers • Relying on “engineer-physician intelligence networks” to develop innovative therapeutic solutions • A portfolio of 2,200 patents

  9. 40 YEARSOF BREAKTHROUGHS & HISTORIC FIRSTS 2011 2010 2008 2006 2002 1998 1995 1994 1993 1982 1981 1973 • Launch of the FIRST Self-Anchoring & Sutureless Heart Valve : PERCEVAL S ™ • XTRA New Sorin Group Autrotransfusion machine • World’s FIRST CRT-D with hemodynamic sensors: PARADYM™ • FIRST semi rigid ring with unique 3D motion (Memo 3D™) • First oxygenator with integrated arterial filter – SORIN* Synthesis™ • World’s FIRST sensor to optimize patient hemodynamics • First dual chamber adult oxygenator – DIDECO* Avant™ • World’s FIRST dual-chamber ICD implant: ELA Medical* DEFENDER™ • World’s FIRST implant of a bi-ventricular pacing system (ELA Medical) • First newborn oxygenator – DIDECO Lilliput™ • FIRST implant of a biological stented heart valve (MITROFLOW*™) • World’s FIRST microcomputer within an ELA Medical’s pacemaker • FIRST modular heart lung machine by STOECKERT* * These companies were gradually merged to build the strong unified brand that Sorin Group represents today

  10. RoW 15% 15% Japan 9% 9% 48% Europe 48% €746 million NorthAmerica 28% 28% A GLOBAL PRESENCE Current R&D and Manufacturing Locations Sales By Geography CARDIAC RHYTHM MANAGEMENT (CRM) CARDIOPULMONARY HEARTVALVES Mirandola (Italy) Munich (Germany) Denver (USA) Clamart (France) Minneapolis (USA) Meylan (France) Saluggia (Italy) Vancouver (Canada)

  11. TECHNOLOGICAL LEADERSHIP - SOME EXAMPLES PROJECT HIGHLIGHTS LinOx (Leadership in Oxygenation) Technological and industrial innovation CARDIOPULMONARY Remote Monitoring First pilot system trial CARDIAC RHYTHM MANAGEMENT Perceval STM Self-Anchoring Sutureless Heart Valve HEARTVALVES Strong customer Support (surgeons)

  12. EXECUTIVE LEADERSHIP TEAM André-Michel BALLESTERChief Executive Officer Davide BIANCHI Heart Valves Stefano DI LULLO Cardiac Rhythm Management Michel DARNAUD Cardiopulmonary & Intercontinental Kieran TUITE Corporate Operations Edward ANDRLE Strategy & Business Development Brian SHERIDANLegal Stéphane BESSETTE Human Resources & Communication Demetrio MAURO Finance & IT

  13. SORIN GROUP VISION • A global leader innovating in the attractive €20 billion Cardiovascular Market • The market leader in Cardiopulmonary • A growing player in the Heart Valves and Cardiac Rhythm Management arenas, with a strong European franchise • A company with a multi-cultural management team and a simplified organization WE ARE… • Continue to invest in technological innovation, for sustainable, profitable long-term growth WE WILL…

  14. Cos’è Perceval S? Perceval è un sistema innovativo per il trattamento della stenosi aortica. Sorin Group propone al cardiochirurgo: • Innovazione • Una nuova terapia • Un nuovo sistema curativo

  15. ValvoladiPericardioBovino • Disegno a doppiofogliodipericardio con • >20 annidiesperienza • Fissaggio del tessuto • Trattamentodetossificante • Dispositivo di ancoraggio • Lega auto-espandibile • Geometria “Double ring” • Design speciale del supporto • Ricoperto di Carbofilm Perceval S: Progettata attorno ad una valvola comprovata PERCEVAL S 16

  16. Perceval S: piattaforma provata clinicamente Valvola in Pericardio Bovino > 20 ANNI DI ESPERIENZA • Disegno valvola - doppio foglio di Pericardio - cross stitches - Performance eccellenti Tessuto Valvola - Pericardio Bovino - detossificazione • Dispositivo di Ancoraggio • Disegno speciale Montanti • Geometria a doppio anello • Lega ad auto Espansione • Rivestimento in Carbofilm

  17. Componente Pericardica : Struttura a Doppio Foglio La configurazione finale è ottenuta da un unico foglio composto da due: un foglio di pericardio a forma di tricuspide è suturato ad un secondo usando fili rivestiti di Carbonio turbostratico(CarbofilmTM). Foglio Funzionale interno Foglio interno Funzionale Foglio esterno di supporto Beneficio: apertura cilindrica con bassi gradienti pressori e meno turbolenze

  18. Il dispositivo di ancoraggio: Sistema Auto-Ancorante Anello outflow smussato ANELLO OUTFLOW (Livello giunzione Sinotubulare) Montanti Sinusoidali (Seni di Valsalva) Montanti commissurali IANELLO INFLOW RING (Livello annulare)

  19. Il dispositivo di ancoraggio: Montanti Auto-Ancoranti Supporto alla Valvola Montanti Commissurali Montanti Sinusoidali • Ancoraggio • Adatta con diverse anatomie del seno di Valsalva , no lrigurgiti paravalvolari • Previene Migrazioni Lega auto-espansione Adattamento alla Radice Aortica Beneficio: auto-ancorante, stabile, senza suture

  20. Il dispositivo di ancoraggio :Carbofilm Physical Vapour Deposition High Vacuum Chamber (room temperature) Electric Field spessore 0.5µm Beneficio: Carbofilm ottimizza emocompatibilità e biocompatibilità

  21. Perceval S • Impiantata con Tecnica Chirurgica Standard a cuore aperto • Adatta per MICS • Pericardio Bovino per performance di durata ed emodinamica • Derivata da esperienza 20 anni Tecnologia Pericarbon Freedom Sorin • Tecnologia Lega Superelastica ad Auto – Espansione • Curativa –rimozione valvola calcifica • Anatomica –adatta all’anatomia del paziente • Senza fili di sutura • Collassabile • Reduce tempi di X-clamping & procedurali • Eccellente performance Emodinamica

  22. Sorin S.p.A. Via Benigno Crespi, 17 20159 Milano – Italy www.sorin.com

More Related